APA (7th ed.) Citation

Butler, L. M., Joshua, A. M., Scheinberg, T., Kench, J., Stockler, M., Mahon, K. L., . . . Horvath, L. G. Pharmacodynamics effects of CDK4/6 inhibitor LEE011 (ribociclib) in high-risk, localised prostate cancer: A study protocol for a randomised controlled phase II trial (LEEP study: LEE011 in high-risk, localised Prostate cancer). BMJ Publishing Group.

Chicago Style (17th ed.) Citation

Butler, Lisa M., et al. Pharmacodynamics Effects of CDK4/6 Inhibitor LEE011 (ribociclib) in High-risk, Localised Prostate Cancer: A Study Protocol for a Randomised Controlled Phase II Trial (LEEP Study: LEE011 in High-risk, Localised Prostate Cancer). BMJ Publishing Group.

MLA (9th ed.) Citation

Butler, Lisa M., et al. Pharmacodynamics Effects of CDK4/6 Inhibitor LEE011 (ribociclib) in High-risk, Localised Prostate Cancer: A Study Protocol for a Randomised Controlled Phase II Trial (LEEP Study: LEE011 in High-risk, Localised Prostate Cancer). BMJ Publishing Group.